TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
HHS announced an updated National Plan to Address Alzheimer’s Disease and Related Dementias on Oct. 22, 2026, replacing six prior goals with four priorities. Related federal initiatives include up to $48.8 million for research projects and a new FDA prevention accelerator; their eventual effects on care and access are not yet known.
The U.S. Department of Health and Human Services updated the National Plan to Address Alzheimer’s Disease and Related Dementias on Oct. 22, setting four priorities that emphasize dementia risk reduction, faster development of prevention and treatment approaches, dementia care, and caregiver support. HHS announced the revision alongside federal research initiatives, including up to $48.8 million in ARPA-H project investments and a new FDA program focused on Alzheimer’s prevention.
The revised plan replaces six historical goals with four. HHS says the new framework will promote risk reduction across the lifespan, accelerate work on preventing and treating Alzheimer’s and other dementias, incorporate dementia care, and strengthen support for caregivers. The announcement describes priorities and related initiatives; it does not report that a new treatment or prevention method has been proven effective.
The largest listed research award is up to $41 million to Mass General Brigham researchers, who will lead a multi-institutional platform trial. The trial is intended to test drugs already approved for other conditions for possible use in Alzheimer’s, alongside supplements, plant-derived products and other compounds. ARPA-H is also awarding $2.75 million to the University of California, San Francisco, to complement existing work on sleep-related risks and early protein dysfunction.
Separately, the FDA launched an Alzheimer’s Prevention Accelerator within its new Neuroscience Advancement and Innovation Nexus program. HHS also said the Administration for Community Living will expand brain-health resources and training for elder-justice professionals, including lawyers and social workers. Other planned efforts include dementia training and screening, behavioral-health and crisis-response resources, public-health work, research into diagnostic delays and economic burdens, a review of prevention evidence, and testing a lifestyle intervention for people with mild cognitive impairment.
Research, Prevention and Care Priorities
The update links research with earlier detection, risk reduction and support outside clinical trials. Its scope includes caregivers and professionals who work with older adults, as well as people at risk of or living with cognitive decline. The elder-justice training component addresses the needs of professionals seeking to prevent abuse and financial exploitation of older adults.
The awards could support research into whether existing drugs or other compounds merit further study, while the FDA accelerator is intended to foster new prevention approaches. These are research and program-development steps, not evidence that the approaches already work. The plan’s practical importance will depend partly on what studies find and whether resulting advances become available to patients and caregivers.
The Alzheimer’s Association welcomed the administration’s focus on innovation but stressed that access matters alongside research progress. In an email to MedPage Today, the group pointed to Medicare beneficiaries’ potential access to blood-based biomarker testing and urged Congress to pass the bipartisan Alzheimer’s Screening and Prevention Act. That is the association’s policy position; the HHS announcement does not establish that the legislation will pass or that Medicare coverage will change.
Alzheimer's risk reduction supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Federal Plan Is Changing
The National Plan to Address Alzheimer’s Disease and Related Dementias is a federal strategy that brings together goals and initiatives across agencies. The Oct. 22 announcement changes its structure from six historical goals to four broader priorities, while describing several projects intended to support the revised approach.
The initiatives span different stages of work: a platform trial will evaluate candidate interventions, the FDA accelerator is intended to foster prevention approaches, and other programs focus on training, screening, public health and care. The announcement also describes research into diagnostic delays and dementia’s economic burden. These efforts are related parts of the update, but the source material does not specify a single timetable or outcome for the overall plan.
“Under President Trump, HHS is shifting the national strategy toward prevention, earlier detection, and faster development of better diagnostics and treatments.”
— HHS Secretary Robert F. Kennedy Jr., in an HHS news release
dementia caregiver support products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial Results and Patient Access
The announcement sets out priorities and projects, but does not provide trial timelines, enrollment details or results. It is not yet clear which candidate drugs, supplements, plant-derived products or other compounds will be tested first, or whether any will show benefit for Alzheimer’s. The stated ARPA-H amounts are described as investments of up to those sums, rather than as confirmed final expenditures.
The source material also does not specify when the FDA accelerator will produce recommendations or programs, how the expanded training and screening efforts will be measured, or how widely the initiatives will reach. No Medicare coverage decision for blood-based biomarker testing is announced. The Alzheimer’s Association’s request for congressional action remains a policy appeal, not a change in current coverage.
early detection Alzheimer's test kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Research and Rollout Milestones
Mass General Brigham researchers are expected to lead the multi-institutional platform trial, while the UCSF award will complement ongoing work on sleep-related risks and early protein dysfunction. The next concrete details to watch for are which interventions enter testing, when studies begin, and how results are reported. HHS agencies will also need to carry out the announced training, screening, public-health and caregiver-related initiatives.
The FDA’s new accelerator is another development to follow as the agency works to foster Alzheimer’s prevention approaches. Separately, Congress could consider the bipartisan Alzheimer’s Screening and Prevention Act, which the Alzheimer’s Association cited in its call for broader access to biomarker testing. The source does not give a legislative schedule or confirm any pending coverage decision.
brain health training for caregivers
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What changed in the national Alzheimer’s and dementia plan?
HHS replaced six historical goals with four priorities: reducing dementia risk, accelerating prevention and treatment work, adding dementia care components, and strengthening caregiver support.
How much research funding did HHS announce?
HHS described a collective ARPA-H investment of up to $48.8 million. That includes up to $41 million for a Mass General Brigham-led platform trial and $2.75 million for Alzheimer’s research at UCSF.
Does the update announce a new proven Alzheimer’s treatment?
No. The announcement describes research that will test possible interventions, including drugs approved for other conditions and other compounds. It does not report that a candidate has been shown to prevent or treat Alzheimer’s.
What is the FDA’s Alzheimer’s Prevention Accelerator?
It is a new FDA initiative within the agency’s Neuroscience Advancement and Innovation Nexus program. The agency says the program is intended to foster approaches to prevent or delay cognitive decline due to Alzheimer’s.
Will Medicare coverage for Alzheimer’s blood tests change?
The announcement does not make a Medicare coverage decision. The Alzheimer’s Association called on Congress to pass the bipartisan Alzheimer’s Screening and Prevention Act and said access to blood-based biomarker testing matters.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
